provid key takeaway firesid chat held
biomarin gilead global
biomarin spiegelman cfo hank fuch presid management
believ rel low phiii fviii level follow valrox treatment
attribut time costicosteroid treatment therefor management
optim phiii on-demand prophylaxi treatment note
management identifi reason non-respond valrox
management believ even overal respons rate valrox would still
satisfactori management provid detail design phiii studi valrox
slide expect studi enrol complet
accord management survey hematologist anticip valrox penetr
follow launch year slide management see
sangamo direct competitor valrox management
believ strong threat year behind valrox
target patient popul exist
immun capsid achondroplasia studi management mention
effect vosoritid reflect design phiii
trial establish vosoritid effect placebo long-term
follow-up data demonstr vosoritid effect height increas studi
power detect increas growth veloc clinic
relev primari endpoint annual growth veloc agv reflect
fact product receiv approv variou indic
base agv effect tradit growth hormon therapi
cm height gain nearli achiev vosoritid studi one year ago
demonstr end phiii trial vosoritid efficaci least
equal superior growth hormon treatment pku management
expect two gener enter market elimin kuvan sale
biomarin work close pku patients/clin therefor kuvan may still
prefer pku medicin addit given pegvalias approv
age year wherea kuvan chiefli target pediatr kuvan gener
expect major impact pegvalias day
management provid updat clinic implic vosoritid
use achondroplasia addit long-term follow-up management present
unblinded/pivot vosoritid data detail corticosteroid treatment
driver low fviii level phiii compar phii valrox studi new
biolog capsid potenti ind next gener biomarin
robert bradway ceo david melin evp cfo management note
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
drug price discuss dc key investor debat
wide rang possibl outcom despit uncertainti management state
compani posit well oper go futur context
management note slow revenu legaci product buffer
extent off-set strength pipelin recent drug launch
continu success exist growth product management remain confid
potenti therapi patient nsclc remind data report
earlier week show orr clean safeti profil encourag
initi durabl data origin note addit data
solid tumor expect emso end month despit
posit data lung cancer management withheld comment non-lung indic
note treatment environ differ across cancer-typ
clariti target indic compani regulatori strategi
made avail data releas management also emphas product
candid evalu part broader oncolog program
bite platform management note end year addit data
share egfr viii bite glioblastoma along
hle bite aml management remain commit capit alloc
strategi defin prior updat focu grow dividend continu
share repurchas amgen soliri biosimilar abp ask
whether eu studi suffici global approv management comment
studi enrol management global regulatori strategi
management state remain confid growth aimovig despit
competit dynam cgrp market possibl oral
competitor drug well posit management provid updat
litig repatha vs praluent though management emphas
import increas access older patient higher-risk
gilead daniel oday chairman ceo investor wait
hear new ceo oday plan reshap compani come month
explain strategi evolut grand new vision
importantli ceo day indic head expect
provid detail around oncolog strategi management note
prepar launch filgotinib management excit potenti expand
label beyond ra ibd specif highlight upcom uc pivot studi
investor focus evolv price debat
potenti implic variou propos come dc management note
sinc compani focus volum growth less reliant price
increas good posit manag impact drug price
propos management remain bullish hiv even lose exclus
biktarvi due potenti long-act antiretrovir therapi
administ once-quarterli chang standard care ii on-go
effort hiv cure management remain commit cell therapi look
opportun earlier line treatment solid tumor management reiter
commit current nash program depend atla read
later year gilead acceler effort reconsid strategi management
state continu rebuild manag team announc
new cfo come soon effort find new chief scientif offic
underway ceo day expect full team place later
steven stein christiana stamouli cfo gvhd phiii
data jakafi steroid-refractori acut
steroid-refractori chronic studi remain track readout jakafi
evalu best avail therapi bat studi management
note efficaci bat report pool fashion comparison
jakafi management previous estim durat therapi jakafi steroid-
refractori acut gvhd month initi use management continu
confid speak patient follow jakafi approv
set phiii data itacitinib first-lin acut gvhd
studi remain track data phiii
studi first-lin chronic gvhd expect phiii data
ruxolitinib cream atop dermat avail phiii data
vitiligo expect updat pivot data fgfr inhibitor
pemigatinib cholangiocarcinoma cca present esmo management
confirm dataset form basi nda cca expect
management reiter data inhibitor parsaclisib follicular
lymphoma margin zone lymphoma mantl cell lymphoma
avail antibodi data msi-high
endometri cancer anal cancer expect merkel cell
carcinoma like come later jakafi life cycl extens program management
indic updat extend releas formul data
combin studi like avail updat target
discoveri beyond jak mpn like avail management indic
open busi develop near-term would focu
hematolog oncolog
act financi advisor tobristol-my squibb compani
relat agreement celgen corpor celgen
inc would acquir global right
otezla apremilast announc august transact
pursuant merger agreement celgen propos
transact subject celgen enter consent decre
feder trade commiss connect pend merger close
pend merger satisfact customari close condit
price target base dcf model discount rate
termin valu rate onward incorpor risk-adjust estim
pipelin candid risk commerci execut current product
clinic regulatori risk associ current clinic program esp
peg-pal vosoritid orphan asset price well management abil deliv
expens manag achiev out-year margin target
deriv price target dcf use discount rate
forecast free cash flow base explicit revenu project use
termin growth rate onward base case project
peak sale jakafi peak total revenu late-stag
develop asset itacitinib ruxolitinib cream forecast peak risk-adjust sale
respect also project aggreg peak
sale early-stag pipelin risk price target includ jakafi sale
expect poor phiii data itacitinib and/or ruxolitinib cream failur
and/or minim success early-stag pipelin asset
price target base dcf use discount rate
termin growth rate model explicit product revenu bulk
gilead revenu deriv antivir product compris gilead
hepat hcv hiv franchis hcv revenu driver harvoni sovaldi epclusa
vosevi hiv product includ atripla truvada viread stribild taf-bas
regimen key non antivir product axi-cel blood cancer risk includ
deceler growth hcv sale volatil hiv franchis poor axi-cel launch
pipelin failur
inform opinion research prepar co llc and/or and/or morgan
stanley mexico de bolsa de and/or canada limit use disclosur section includ morgan
stanley co llc mexico de bolsa de canada limit affili
necessari
import disclosur stock price chart equiti rate histori regard compani subject report pleas see morgan
stanley research disclosur websit www morganstanley com/researchdisclosur contact invest repres
research broadway attent research manag new york ny usa
valuat methodolog risk associ recommend rate price target referenc research report pleas contact client
support follow us/canada hong kong latin america london
singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
follow analyst herebi certifi view compani secur discuss report accur express
receiv receiv direct indirect compens exchang express specif recommend view report matthew
unless otherwis state individu list cover page report research analyst
morgan stanley research publish accord conflict manag polici avail
www morganstanley com/institutional/research/conflictpolici portugues version polici found www morganstanley com br
import us regulatori disclosur subject compani
august benefici own class common equiti secur follow compani cover morgan
within last month manag co-manag public offer offer secur alector inc argenx se avrobio inc
within last month receiv compens invest bank servic alector inc argenx se avrobio inc
next month expect receiv intend seek compens invest bank servic akebia
within last month receiv compens product servic invest bank servic amgen inc
within last month provid provid invest bank servic invest bank client relationship
follow compani alder biopharmaceut inc alector inc alnylam
within last month either provid provid non-invest bank securities-rel servic and/or past
enter agreement provid servic client relationship follow compani amgen inc beigen ltd biogen inc biomarin
 co llc make market secur alder biopharmaceut inc alector inc
equiti research analyst strategist princip respons prepar research receiv compens base upon
variou factor includ qualiti research investor client feedback stock pick competit factor firm revenu overal invest bank
revenu equiti research analyst strategist compens link invest bank capit market transact perform morgan
stanley profit revenu particular trade desk
affili busi relat companies/instru cover research includ market make provid
liquid fund manag commerci bank extens credit invest servic invest bank sell buy
custom securities/instru compani cover research princip basi may posit debt
compani instrument discuss report trade may trade princip debt secur relat deriv
subject debt research report
certain disclosur list also complianc applic regul non-u jurisdict
use rel rate system use term overweight equal-weight not-rat underweight see definit morgan
stanley assign rate buy hold sell stock cover overweight equal-weight not-rat underweight equival
buy hold sell investor care read definit rate use morgan stanley research addit sinc morgan stanley research
contain complet inform concern analyst view investor care read morgan stanley research entireti infer
content rate alon case rate research use reli upon invest advic investor decis buy sell
stock depend individu circumst investor exist hold consider
august
stock rate describ appli fundament equiti research appli debt research produc firm
disclosur purpos accord nasd nyse requir includ categori head buy hold sell alongsid
rate overweight equal-weight not-rat underweight assign rate buy hold sell stock cover
overweight equal-weight not-rat underweight equival buy hold sell repres recommend rel weight see
definit satisfi regulatori requir correspond overweight posit stock rate buy recommend correspond
equal-weight not-rat hold underweight sell recommend respect
data includ common stock adr current assign rate invest bank client compani receiv invest
bank compens last month due round decim percentag provid total column may add exactli
overweight stock total return expect exceed averag total return analyst industri industri team coverag univers
risk-adjust basi next month
equal-weight stock total return expect line averag total return analyst industri industri team coverag univers
risk-adjust basi next month
not-rat nr current analyst adequ convict stock total return rel averag total return analyst
industri industri team coverag univers risk-adjust basi next month
underweight stock total return expect averag total return analyst industri industri team coverag univers
risk-adjust basi next month
unless otherwis specifi time frame price target includ morgan stanley research month
attract analyst expect perform industri coverag univers next month attract vs relev broad
market benchmark indic
in-lin analyst expect perform industri coverag univers next month line relev broad market
benchmark indic
cautiou analyst view perform industri coverag univers next month caution vs relev broad market
benchmark indic
benchmark region follow north america latin america relev countri index latin america index europ
europ japan topix asia relev countri index sub-region index ac asia pacif ex japan index
import disclosur morgan stanley smith barney llc custom
